 |
 
|
|
|
|
Wednesday, September 28, 2005
|
07.50 a.m
|
BREAKFAST
BUFFET at the Klosterwirt |
|
08.30 a.m
|
L-22
Thrombocyte development in Zebrafish |
|
|
Robert
Handin, Harvard Medical School, Boston MA, USA |
|
09.10 a.m
|
L-23 Dynamic
imaging of pericellular proteolysis |
|
|
Peter
Friedl, Univ. of Würzburg, Würzburg, Germany |
VI. Thrombosis
and disease
|
10.20 a.m
|
L-24 Tissue factor and atherothrombosis |
|
|
James Hathcock, Mount Sinai Medical Center, New York, USA |
|
11.00 a.m
|
L-25
Thrombotic complications in ET:
Clinical facts and biochemical riddles
|
|
|
Petro E.Petrides, University of Munich, Munich,
Germany
|
|
11.30 a.m
|
L-26
Aspirin sensitive, coumarin resistant platelet mediated microvascular
disturbances: minor and major thrombosis and bleeding manifestations in
ET and PV |
|
|
Jan Jacques Michiels, Rotterdam University, Rotterdam, The Netherlands |
|
12.10 p.m
|
Oral Poster Presentations |
|
02.00 p.m
|
L-27 Platelets in
the onset of atherosclerosis |
|
|
Meinrad Gawaz, University of Tübingen, Tübingen,
Germany |
|
02.40 p.m
|
L-28 Met Oncogene:
a link between cancer and hemostasis |
|
|
Carla Boccaccio & Paolo Comoglio, University of Torino, Torino, Italy |
|
03.40 p.m
|
L-29 Activated
Protein C and cebrovascular thrombosis |
|
|
John Griffin, The Scripps Research Institute, La Jolla CA, USA
|
VII. Novel Targets for
Anti-Thrombotic Therapy
|
04.20 p.m
|
L-30 Ectonucleotidases of the
CD39/NTPDase family modulate platelet activation and thrombus
formation: potential as therapeutic targets |
|
|
Simon Robson, Harvard Medical Schoo, Boston MA, USA |
|
05.00 p.m
|
L-31 P2Y Receptors
|
|
|
Christian Gachet, Etablissement Francais, Strasbourg, France |
|
05.40 p.m
|
L-32 Novel platelet
receptor targets |
|
|
David
Phillips, Portola Company, San Francisco CA, USA |
|
08.00 p.m
|
FAREWELL DINNER WITH BAVARIAN MUSIC |
|
